The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder-Reference-Cited by-同舟云学术

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder

Published:2021-07-22 Issue:11 Volume:38 Page:1120-1130
ISSN:1091-4269
Container-title:Depression and Anxiety
language:en
Short-container-title:Depression and Anxiety

Author:

Daly Ella J.¹^ORCID,Turkoz Ibrahim²,Salvadore Giacomo³,Fedgchin Maggie³,Ionescu Dawn F.⁴,Starr H. Lynn¹,Borentain Stephane¹,Trivedi Madhukar H.⁵^ORCID,Thase Michael E.⁶,Singh Jaskaran B.⁴

Affiliation:

1. Department of Neuroscience Medical Affairs Janssen Scientific Affairs, LLC Titusville New Jersey USA

2. Department of Statistics & Decision Sciences Janssen Research & Development, LLC Titusville New Jersey USA

3. Department of Neuroscience Janssen Research & Development, LLC Titusville New Jersey USA

4. Department of Neuroscience Janssen Research & Development, LLC San Diego California USA

5. Department of Psychiatry University of Texas Southwestern Medical Center Dallas Texas USA

6. Department of Psychiatry, Perelman School of Medicine University of Pennsylvania and the Corporal Michael J. Crescenz VAMC Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Psychology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/da.23193

Reference32 articles.

1. Diagnostic and Statistical Manual of Mental Disorders

2. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study

3. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)

4. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment;Journal of Psychopharmacology;2024-08-07

2. Fármacos enteógenos y la depresión resistente al tratamiento: Una revisión narrativa;Psicumex;2024-06-01

3. Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review;Frontiers in Psychiatry;2024-05-15

4. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery–Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire;CNS Spectrums;2024-04-01

5. The effects of prophylactic use of esketamine on postoperative depression and quality of life: a meta-analysis;Minerva Anestesiologica;2024-03